Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
MINNEAPOLIS, Jan. 29, 2018 -- DiaMedica Therapeutics Inc. (TSXV:DMA) (OTCQB:DMCAF), today announced that Mr. Rick Pauls, its President and CEO, will present at Noble Capital Markets’ Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Tuesday, January 30th at 01:30 pm EST - Studio 1.
About DiaMedica Therapeutics:
DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and on the OTCQB under the trading symbol “DMCAF”.
DiaMedica’s lead product candidate DM199, a recombinant (synthetic) form of the KLK1 protein, is in development for the treatment of neurological and kidney diseases.
For more information, please visit www.diamedica.com. Follow us on social media - Twitter, LinkedIn.
About Noble Capital Markets, Inc.
Noble Capital Markets, established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology, transportation & logistics and natural resources sectors. The company has offices in Boca Raton, New York and Boston and St. Louis. In addition to NobleCon - the annual multi-sector investor conference - and the Media, Finance & Investor Program - produced in partnership with the National Association of Broadcasters (NAB) and held each spring in Las Vegas - Noble hosts numerous “non-deal” corporate road shows throughout the year across the United States and Canada. Members: FINRA, SIPC, MSRB. www.noblecapitalmarkets.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.
For further information, please contact:
Paul Papi
Vice President of Business Development
DiaMedica Therapeutics Inc.
Two Carlson Parkway, Suite 260
Minneapolis, MN
Phone: (617) 899-5941
[email protected]
